SMN1 and proximal spinal muscular atrophy: Risdiplam, an SMN2 splicing modifier, is 1 of 3 SMN-restoring therapies approved for use in humans with SMA and capable of increasing full-length SMN protein levels across a range of cells and tissues (58).